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The Caveolin-1 Binding Domain of HIV-1
Glycoprotein gp41 Is an Efficient B Cell Epitope
Vaccine Candidate against Virus Infection
vaccine preparation should have both components to
stimulate T cell responses and to elicit anti-HIV antibod-
ies. Currently, more than 20 HIV vaccines designed to
stimulate T cell responses are in clinical trials, whereas
no vaccine that is capable of stimulating the production
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brane trafficking (Liu et al., 2002; Smart et al., 1999; vanFrance
Deurs et al., 2003). Lipid rafts containing caveolin-1 as
the structural protein component are known as caveo-
lae, which are 50–100 nm invaginations of the plasmaSummary
membrane with unique endocytic properties. Caveolin-1
is a ubiquitous cholesterol binding protein within theCaveolin-1 is a scaffolding protein that organizes and
plasma membrane where it forms a hairpin-like struc-concentrates specific ligands within the caveolae mem-
ture. Caveolin-1 has a scaffolding domain located inbranes. We identified a conserved caveolin-1 binding
the juxtamembranous region of the N-terminal domain,motif in the HIV-1 transmembrane envelope glycopro-
referred to as caveolin-scaffolding domain, that is re-tein gp41 and designed several synthetic peptides,
sponsible for the oligomerization of caveolin-1 and rep-referred to as CBD1, corresponding to the consensus
resents the site for binding to various proteins (Okamotocaveolin-1 binding domain in gp41. In rabbits, these
et al., 1998). By using the caveolin-scaffolding domainpeptides elicit the production of antibodies that inhibit
as a receptor, two binding motifs, φXφXXXXφ and
infection of primary CD4 T lymphocytes by various
φXXXXφXXφ, have been isolated from a phage display
primary HIV-1 isolates. Interestingly, gp41 exists as a
library where φ is any one of the aromatic amino acid
stable complex with caveolin-1 in HIV-infected cells. residues W, F, or Y and X is any other amino acid residue
Anti-CBD1 peptide antibodies, therefore, might be (Couet et al., 1997). Interestingly, one of these two motifs
functional by inhibiting the potential interaction of is found in most of caveolin-1 binding proteins.
gp41 with caveolin-1. Because of their capacity to elicit While lipid rafts appear to be small in size and dis-
antibodies that inhibit the different clades of HIV-1, persed all around the plasma membrane of nonpolarized
CBD1-based peptides may represent a novel synthetic cells, the interaction of raft-associated proteins with
universal B cell epitope vaccine candidate for HIV/ their ligands or their crosslinking with antibodies leads
AIDS. Moreover, such peptides could also have an to the oligomerization of raft components (Harder et al.,
application as a therapeutic vaccine since CBD1-spe- 1998). A number of pathogens including viruses have
cific antibodies are rare in HIV-infected individuals been reported to use lipid rafts and caveolae as the
from several geographic origins. endocytosis route or to exert their pathogenic effects
(Campbell et al., 2001). In the case of HIV-1, several
Introduction groups have reported the implication of lipid rafts in
viral entry (Manes et al., 2000; Nisole et al., 2002a) and
Twenty years after its discovery as the etiological agent budding processes (Nguyen and Hildreth, 2000; Ono
of AIDS, HIV continues to be a major health problem and Freed, 2001).
throughout the world, with more than 40 million cases HIV entry into permissive cells is initiated by viral
external and transmembrane envelope glycoproteinsand 4 million deaths (Fauci, 2003). Consequently, there
gp120 and gp41, respectively. The sequential bindingis an urgent need for the development of an effective
of gp120 to CD4 and a chemokine receptor triggersHIV vaccine. It is now widely believed that a successful
gp41 to undergo substantial folding, which leads to the
insertion of the N-terminal hydrophobic, glycine-rich*Correspondence: ara.hovanessian@univ-paris5.fr
“fusion” peptide in the membrane of target cells. There4Present Address: UPR 2228 CNRS, UFR Biome´dicale des Saints-
are two hydrophobic heptad repeat domains at thePe`res, Universite´ de Paris V, 45 Rue des Saints-Pe`res, 75270 Paris
Cedex 6, France. N-terminal and C-terminal of the gp41 ectodomain (re-
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ferred to as N-HR and C-HR) with a sequence motif pretreatment of cells with the cholesterol-chelating
agent methyl -cyclodextrin, the majority of caveolin-1characteristic of coiled-coils that plays an essential role
becomes soluble in the lysis buffer containing the non-for membrane fusion (Eckert and Kim, 2001). A hydro-
ionic detergents. An example of caveolin-1 solubilizationphilic, nonhelical loop region of 25–30 residues charac-
is presented in Figure 1B. Still another problem is theterized by an intrachain disulfide bond connects these
fact that caveolin-1 forms high molecular weight homo-domains. Crystallographic studies have suggested that
oligomeric complexes (Scheiffele et al., 1998) that re-during the fusion process, N-HR and C-HR become
main in the stacking gel. Interestingly, precipitation offolded in a very stable six-helix bundle structure in which
proteins by 5% trichloroacetic acid (TCA) results in dis-three N-HR domains form an interior core, forming three
sociation of such complexes into the monomeric caveo-hydrophobic grooves onto which three C-HR domains
lin-1 (Figure 1C, MT4). In activated peripheral bloodpack in the reverse orientation (Chan et al., 1997, 1998).
mononuclear cells (PBMC), caveolin-1 is detectable asThis six-helix bundle displays substantial affinity for lipid
a protein of 95 kDa that could correspond to a stablebilayers (Shu et al., 2000), and thus it brings the viral
tetrameric form, since upon TCA precipitation it be-and cellular membranes into close proximity for the
comes partially dissociated to proteins that appear tomembrane fusion process. The determinants for the six-
correspond to trimeric, dimeric, and monomeric caveo-helix bundle-membrane interaction leading to mem-
lin-1 (Figure 1C, PBMC). This latter profile of caveolin-1brane fusion and HIV entry remain to be elucidated.
is also observed in PBMC pretreated with methylWe identified a highly conserved caveolin-1 binding
-cyclodextrin (not shown).motif in gp41 in which the three aromatic amino acids
Among HIV-1 structural proteins, gp41 has a distinctare always tryptophan. Accordingly, synthetic peptides
caveolin-1 binding motif, 623WNNMTWMEW631, that starts(referred to as CBD1) containing this caveolin-1 binding
at amino acid residue 623 at the end of the loop betweenmotif in gp41 bind specifically caveolin-1. Furthermore,
the two helical structures, with the last four amino acidimmunoprecipitation of gp41 from HIV-infected cells re-
residues overlapping the C-HR domain. The three tryp-sults in the recovery of the gp41/caveolin-1 complex,
tophan residues in this motif are conserved in all of thethus indicating that under physiological conditions gp41
862 HIV-1 isolates from most of HIV clades (Dong et al.,binds caveolin-1. We then demonstrated that several
2001). Intriguingly, the caveolin-1 binding motif is alsoCBD1 peptides reproducibly elicit in rabbits the produc-
conserved between various HIV-2 and SIV isolates (Sup-tion of antibodies that inhibit infection of T lymphocytes
plemental Table S1 available online at http://www.by various primary HIV-1 isolates. An affinity matrix con-
immunity.com/cgi/content/full/21/5/617/DC1/). Thestructed with the CBD1 peptide can purify such antibod-
conservation of the caveolin-1 binding motif amongies. The HIV-specific caveolin-1 binding domain pro-
HIV-1, HIV-2, and SIV isolates suggests that there is avides a novel B cell epitope for the development of
constant selective pressure to preserve this sequenceeffective vaccine candidates against HIV-1 infection.
for a specific function in the infectious cycle of these
retroviruses. In HIV-1, point mutation of W628 to either AResults
or F has been reported to impair the cleavage of the
envelope precursor gp160 (Weng et al., 2000). Thus,
Interaction of gp41 with Caveolin-1
there could be additional selective pressure on the ca-
Antibody-dependent crosslinking of HIV-1 LAI particles
veolin-1 binding motif because of structural require-
anchored in the plasma membrane of permissive MT4 ments necessary for processing of the envelope glyco-
cells causes aggregation of HIV and its colocalization protein precursor. Moreover, the X-ray crystal structure
with the clustered receptors CD4/CXCR4, the cell sur- of gp41 predicts that the conserved W628 and W631 are
face-expressed nucleolin, and the lipid raft-associated involved in the binding of C-HR domain to the small
proteins CD90/CD59 without affecting the organization pocket in the hydrophobic groove of the N-HR trimeric
of CD45 known to be systematically excluded from lipid coiled coil (Chan et al., 1998), thus further emphasizing
rafts (Nisole et al., 2002a). Under similar circumstances, the importance to conserve these aromatic residues
caveolin-1 in the plasma membrane also becomes clus- as tryptophan.
tered and colocalizes with the HIV signal, whereas in From the alignment of the amino acid sequence of
uninfected control cells, caveolin-1 remains uniformly HIV-1 isolates, we deduced the composition of the ca-
distributed at the cell periphery (Figure 1A). In contrast veolin-1 binding domain in gp41. The synthetic peptide,
to previous reports, caveolin-1 is expressed constitu- referred to as CBD1, is composed of 16 amino acid
tively in primary cells implicated in HIV infection, such residues, SLEQIWNNMTWMQWDK, corresponding to
as lymphocytes, macrophages, and dendritic cells (Har- the region in gp41 of HIV-1 from amino acid positions
ris et al., 2002) (Supplemental Data). 618–633 (Dong et al., 2001). Besides the three conserved
The recovery of caveolin-1 from a given cell type is W residues, the other amino acid residues in CBD1 are
dependent on the nature of the nonionic detergent used at least 90% conserved among various HIV-1 isolates,
in the cell-lysis buffer (Schuck et al., 2003). In human while the remaining 10% manifest mostly semiconserva-
CD4 MT4 T lymphocytes, only a very small proportion tive changes. The binding of CBD1 to caveolin-1 was
of caveolin-1 is recovered as a soluble monomeric pro- observed by using biotinyl-CBD1 and Triton-X-100 ex-
tein by using lysis buffers I and II, which contains Triton- tracts from MT4 cells. CBD1 binds caveolin-1 in a dose-
X100 and NP-40, respectively, whereas the majority of dependent and -specific manner, as demonstrated by
caveolin-1 remains in the Triton/NP-40-resistant pellet reduced binding in the presence of excess peptide (Fig-
that can be solubilized by SDS. This latter is largely due ure 1D). On intact cells, crosslinking of surface-
anchored biotinyl-CBD1 with an anti-biotin antibodyto direct binding of caveolin-1 to cholesterol, since upon
Synthetic Peptide Immunogens against HIV Infection
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Figure 1. Interaction of gp41 with Caveolin-1
(A) HIV induced aggregation of caveolin-1 in the plasma membrane: MT4 cells preincubated (37C, 45 min) in the absence ( HIV) or presence
of HIV-1 LAI ( HIV) were further incubated (20C, 60 min) with anti-HIV-1 human serum (panels HIV-TR). In a similar experiment, cell-anchored
biotinyl-CBD1 (37C, 30 min) was crosslinked (20C, 60 min) with an anti-biotin mAb (Nisole et al., 2002b). The different antibodies were revealed
by using the corresponding TR or FITC-conjugated antibody as indicated. The laser scanning confocal microscopy shows a crosssection for
each staining with the merge of the two colors in yellow and the corresponding phase contrasts.
(B) Recovery of caveolin-1: MT4 cells preincubated (37C, 60 min) in the absence (Control) or presence of 10 mM methyl -cyclodextrin (MCD)
were extracted in the lysis buffer II. After centrifugation, the supernatant (lanes SN) corresponding to the nonionic-detergent soluble proteins
and the pellet (lanes P) corresponding to nonionic-detergent insoluble material were analyzed by immunoblotting with rabbit anti-
caveolin-1 antibodies.
(C) Dissociation of high molecular weight caveolin-1 complexes: MT4 cells and PBMC extracts in buffer II, as such (lanes TCA) or precipitated
with 5% TCA (lanes TCA), were analyzed by immunoblotting as in (B).
(D) Caveolin-1 binds the CBD1 peptide: extracts from MT4 cells were incubated (4C, 90 min) with 0, 2, 5, 10, and 20 M of biotinyl-
CBD1 (CBD1-B) before recovering peptide bound molecules by avidin-agarose (Nisole et al., 2002b). Specific binding was demonstrated by
preincubation of cell extracts with 50 M of CBD1 () or as such () before addition of biotinyl-CBD1 (10 M). Samples were analyzed by
immunoblotting as in (B). The strong signal in crude cell extracts at the top of the gel (lane E) corresponds to oligomeric caveolin-1.
(E) Coimmunoprecipitation of caveolin-1 with gp41: extracts from HIV-1 LAI infected (HIV-cells) and uninfected (Cells) MT4 cells were immuno-
precipitated with murine mAb against HIV-1 matrix protein p17 and gp41, and extracts were analyzed by immunoblotting with the human
mAb 8D against gp41, murine mAb against p17, and rabbit anti-caveolin-1 antibodies. Lane E represents crude extracts from HIV-infected
cells diluted 1-fold in the electrophoresis sample buffer. Rabbit anti-caveolin-1 antibodies crossreact with the heavy chain of murine IgG in
the immune complexes (marked IgG).
(F) The direct association of gp41 with caveolin-1: extracts from HIV-infected MT4 cells pretreated or not ( or ) with the raft-disrupting
agent OTG were immunoprecipitated with the murine anti-gp41 mAb before analysis by immunoblotting (WB) by using the human mAb 8D
against gp41 (lanes Anti-gp41), rabbit anti-caveolin-1 antibodies (lanes Anti-Cav.), and goat anti-rabbit Ig (lanes Anti-Rabbit).
caused coaggregation of CBD1 with caveolin-1 (Fig- accord with this, immunoprecipitation of gp41 from HIV-
infected cell extracts with a murine mAb resulted in theure 1A).
The capacity of CBD1 to bind caveolin-1 suggests that recovery of gp41 along with caveolin-1 (Figure 1E). This
is a specific event and not a consequence of coassocia-the interaction between gp41 and caveolin-1 is direct. In
Immunity
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tion of gp41 and caveolin-1 with lipid rafts, since caveo- reduced in cultures treated at 75- and 100-fold dilution
of the immune serum, there was a marked increaselin-1 was not coimmunoprecipitated with the HIV matrix
protein p17 (Figure 1E) known to associate with lipid in the level of Triton-insoluble gp41 (Figure 2C). The
quantification of Triton-soluble p17 and Triton-insolublerafts (Nisole et al., 2002a). Accordingly, additional treat-
ment of cell extracts with the raft-disrupting agent gp41 bands observed in infected cultures incubated
with a 100-fold dilution of the immune serum S5 indi-n-octyl-glycoside (OTG) before immunoprecipitation
with the anti-gp41 antibody did not affect the recovery cated that gp41 was increased by 6-fold whereas p17
was decreased by 6-fold compared to the control cul-of the gp41 bound caveolin-1. Rather, OTG treatment
apparently increased the solubility of gp41-caveolin tures treated with the preimmune serum S0. This marked
increase of Triton-insoluble gp41 suggests that anti-complex, since an increased amount of these proteins
was recovered in the immunoprecipitate (Figure 1F). CBD1 antibodies cause its aggregation and accumula-
tion in the plasma membrane by interacting with the
mature gp41 exposed on the cell surface. This couldThe CBD1 Peptide Elicits the Production
then lead to the production of gp120-gp41-deficient HIVof Antibodies that Inhibit HIV Infection
virions that have normal level of Gag proteins. By meta-The CBD1 peptide was immunogenic in rabbits as re-
bolic labeling of infected cells with [35S]methionine/cys-vealed by the gradual production of anti-CBD1 antibod-
teine, we demonstrated that addition of anti-CBD1 anti-ies that also inhibited HIV-1 LAI infection in MT4 cells
bodies to HIV-infected cells at 5 days postinfectionreaching more than 95% inhibition after five immuniza-
caused a marked reduction of cell- and virus-associatedtions (Figure 2, A/1). The inhibition of HIV infection by
gp120, whereas the production of the mature core pro-the immune serums S4 and S5 was not the consequence
tein p24 was not affected (Figure 2D). Under these ex-of a toxic effect on cells, since cell viability was not
perimental conditions, the steady-state level of theaffected (Figure 2, A/2).
Env-precursor gp160 in cells was not affected, thus con-Several preparations of biotinyl- and cysteinyl-CBD1
firming that the effect of anti-CBD1 antibodies is on thepeptides, conjugated or not to a carrier protein, repro-
already cleaved and matured envelope glycoproteins.ducibly elicited the production of specific anti-CBD1
Therefore, as a consequence of gp41 aggregation in theantibodies that inhibited HIV infection (Table 1). Treat-
plasma membrane (Figure 2C), the incorporation of gp41ment of cells with anti-CBD1 antibodies (37C, 1 hr) and
in the budding virus is reduced, leading to decreasedtheir removal by washing before addition of HIV-1 did not
levels of virus-associated gp120 (Figure 2D). Accord-affect virus infection, thus suggesting that the inhibitory
ingly, the gp120/p24 ratio in virus particles was reducedeffect of antibodies is directed against virus particles
by 5-fold. Consequently, anti-CBD1 antibodies could(not shown). Anti-CBD1 antibodies potently inhibited vi-
cause the production of defective virus particles withrus infection when preincubated with HIV before adding
reduced capacity to infect permissive cells (as dis-to cells or added with HIV to target cells, reaching 95%
cussed below in Figure 3D).inhibition at 25- to 150-fold serum dilution and 50%
inhibition at 50- to 200-fold dilution, depending on the
considered immune serum (Table 1; Figure 2, B/1). On The Broad Inhibitory Activity of Anti-CBD1 Antibodies
Anti-CBD1 immune sera (bleeds S5) inhibits HIV infec-the other hand, when anti-CBD1 antibodies were added
2 days postinfection, then there was very little or no tion of primary CD4 T lymphocytes by the X4 HIV-1 LAI
and R5 HIV-1 Ba-L as well as other laboratory-adaptedapparent effect on virus production monitored by the
concentration of p24 in the culture supernatant (Figure or drug-resistant HIV-1 isolates. More importantly, the
immune sera from different immunization protocols in-2, B/2). These observations point out that anti-CBD1
antibodies block an early event in the HIV-infectious hibit primary isolates of HIV-1 belonging to various
clades, with 50% and 95% inhibition occurring at 40-cycle when added to cells together with the virus. In
accord with this, HIV particles lose their capacity to to 200-fold and 25- to 150-fold dilution, respectively
(Table 2). Thus in spite of slight amino acid variationsinfect target cells after preincubation with the immune
serum and centrifugation to remove unbound antibodies in the CBD1-epitope of these different isolates of HIV-1
(Supplemental Table S1), the CBD1 peptide is capable of(Figure 2, B/3). The CBD1-epitope should therefore be
exposed on virus particles before binding to CD4 on eliciting antibodies with broad inhibitory activity. Typical
kinetics of HIV-1 infection in the presence of preimmunepermissive cells. A series of experiments carried out at
31.5C and 37C indicated that the CBD1-epitope is not (S0) and immune (S5) serum are presented in Figures
3A–3C. The infectivity of virus particles recovered froma transient conformational species (data not shown) in
contrast to other cryptic epitopes in gp41 (Golding et infected lymphocytes that were cultured in the presence
of 100-fold diluted immune serum was tested in a single-al., 2002). The CBD1-epitope is even accessible to HIV-1
particles bound to target cells at 20C. Consistent with round infectivity assay (Figures 3D and 3E) by using
HeLa P4C5 cells (see Supplemental Data). For differentthis, anti-CBD1 antibodies have no apparent effect on
the HIV-attachment to permissive cells (data not shown). types of HIV-1 that were tested in Table 2, virions recov-
ered from cultures treated with the immune serum wereConsistently, anti-CBD1 antibodies inhibited HIV-1 in-
fection in a dose-dependent manner. The complete inhi- at least 50% less infectious compared to the corre-
sponding virions recovered from cultures treated withbition of virus infection at 25- and 50-fold dilution of the
immune serum was confirmed by the total absence of the preimmune serum. HeLa P4C5 cells provide a suit-
able experimental system to assay for virion infectivity,Gag precursor p55 and its cleaved matured products,
the core p24 and the matrix p17 (Figure 2C). Interest- since the anti-CBD1 immune sera do not affect HIV in-
fection of such cells (see Supplemental Data).ingly, when the level of Gag proteins was still very much
Synthetic Peptide Immunogens against HIV Infection
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Figure 2. The CBD1 Peptide Induces Antibodies that Inhibit HIV Infection
(A/1 and A/2) Anti-HIV activity of successive bleeds from rabbit ALD after immunization with CBD1 (as described in Table 1): MT4 cells
preincubated with HIV-1 LAI (20C, 60 min) were incubated (37C, 90 min) in the presence of 20-fold dilution of rabbit serum ALD before (S0)
and after different immunizations (S2 to S5). The abscissa gives the percentage of HIV production 6 days postinfection with respect to the
infected control sample (A/1). On the right is the antipeptide titer of each serum corresponding to the dilution of serum giving OD value of
0.5 in ELISA. Cells recovered after 6 days postinfection were assayed for cell viability by the MTT test (A/2) as described before (Callebaut
et al., 1996). The values are presented as OD measurements at 540 nm. Each point represents the mean  SD of quadruplicate samples. No
cytopathic effect, monitored by the formation of syncytia and degradation of nucleosomal DNA (Katsumoto et al., 1990; Laurent-Crawford et
al., 1993), is observed at 6 days postinfection of such MT4 cells.
(B/1 and B/2) Dose-dependent inhibition of HIV infection: MT4 cells were infected with HIV-1 LAI in the presence of rabbit ALD S0 (preimmune)
and S5 (immune serum) at 25- to 100-fold dilution as indicated. In B/1 and B/2, sera were added with HIV infection and 2 days postinfec-
tion, respectively.
(B/3) HIV particles preincubated with anti-CBD1 antibodies loose their infectivity: equivalent aliquots of HIV-1 LAI in the absence or presence
of serum S0 and S5 at 50-fold dilution were incubated at 37C for 45 min. After centrifugation at 100,000 g, the HIV pellet was suspended in
fresh culture medium and used to infect MT4 cells. The virus production in B/1-B/3 was monitored at 5 days postinfection.
(C) Enhanced accumulation of gp41 in HIV-producing cells cultured in the presence of anti-CBD1 antibodies: 5 days postinfection of MT4
cells cultured in the presence of ALD S0 and S5 serum (as in section B/1), Triton X-100 soluble extracts were analyzed by immunoblotting
for the presence of Gag proteins (by using rabbit anti-p24 antibodies and murine mAb p17), whereas Triton-insoluble pellets were analyzed
by immunoblotting for gp41 (using mAb 8D) after solubilization in PAGE sample buffer containing 1% SDS. On the right is the position of
gp41 and the Gag precursor p55 with its partially cleaved product p40, and the mature Gag products p24 and p17.
(D) Reduced incorporation of gp120 into virus particles produced by HIV-infected cells cultured in the presence of anti-CBD1 antibodies: at
5 days postinfection of MT4 cells with HIV-1 LAI, cells were treated with the ALD S0 and S5 serum (at 50-fold dilution) for 24 hr concomitant
with metabolic labeling with [35S]methionine/cysteine. Immunoprecipitated HIV proteins from cell (Cells lanes) and viral (HIV-1 lanes) extracts
were analyzed by SDS-PAGE and labeled proteins revealed by fluorography.
In contrast to HIV-1 infection, not all anti-CBD1 im- ever is the case, the lack of inhibition of HIV-2 infection
by several anti-CBD1 immune sera (Table 2; sections IImune sera could inhibit HIV-2 infection (Table 2). This
latter might be due to the specific nature of the CBD1- and III) indicates that the marked inhibition of HIV-1
isolates by such sera is a specific event exerted by anti-epitope in the transmembrane envelope glycoprotein of
HIV-2. In particular, the three residues just preceding CBD1 antibodies. Indeed, passing through an affinity
matrix constructed with biotinyl-CBD1 markedly re-the caveolin-1 binding motif in HIV-2 is different from
that of HIV-1 (Supplemental Table S1). Therefore, HIV- duced the antibody titer and the anti-HIV activity of the
immune sera. For example, while 95% inhibition oc-2-specific peptides should be used for the generation
of antibodies capable of inhibiting HIV-2 infection. What- curred at 50-fold dilution of the starting rabbit immune
Immunity
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Table 1. Inhibition of HIV-1 Infection by Rabbit Immune Sera Raised against the CBD1-Based Peptides Corresponding to the Caveolin-1
Binding Domain in gp41
Inhibition of HIV-1
ELISA
Rabbit Immunogen Adjuvant Serum Dilution ID 50 ID 95
ALD (im) CBD1-B/Streptavidin CFA/IFA 16,000 110 50
SAN (im) CBD1-B/Streptavidin A:U 800 100 60
DAV (id) CBD1-B A:U 2000 100 50
BRO (id) CBD1 A:U Negative No effect No effect
GEO (im) CBD1-B CFA Negative No effect No effect
KUR (im) CBD1-C CFA 64,000 200 150
LEO (im) CBD1-C CFA 32,000 120 70
MIK (im) CBD1-C/OVA CFA/IFA 16,000 70 25
NOU (im) CBD1-C/OVA CFA/IFA 16,000 50 25
Rabbits were injected intramuscularly (im) or intradermally (id) with the different immunogens. The results are given for the immune sera
collected 2 weeks after the 5th injection (bleeds S5). The adjuvants were either CFA/IFA, IFA or poly(A).poly(U)(A:U). The immunogens used
were the following: CBD1, CBD1-B (biotinyl-CBD1), and CBD1-C (cysteinyl-CBD1). The amino acid sequence of the CBD1 peptides is given
in the Supplemental S1. Streptavidin and ovalbumin (OVA) were used as carrier proteins as indicated. The different sera were titrated by
ELISA against the respective CBD1 peptides. The results are presented as fold dilution of a given immune serum that gives in ELISA an
absorbance value of 0.5 (OD measured at 450 nm). The inhibitory action of anti-CBD1 antibodies against HIV-1 LAI infection was assayed
using MT4 cells. The dilutions of the anti-CBD1 serum giving 95 (ID95) and 50 (ID50) percent inhibition of HIV production (measured by the
concentration of p24 in the culture medium) are given.
erum DAV, the flow-through fraction had no effect. On (Figure 3I,  bars). As neutralizing anti-gp41 antibodies
interferes with a postattachment step (Sattentau et al.,the other hand, the purified antibody exerted 95%
inhibition at 10 g/ml (Figure 3F). Similarly purified 1999) (in contrast to neutralizing anti-gp120 antibodies,
which affect HIV attachment [Valenzuela et al., 1997]),anti-CBD1 antibodies from rabbit serum KUR and LEO
exerted 90% inhibition at 8 g/ml (Figure 3G). It washing of infected cells that have been incubated in
the presence of mAb 2F5 and anti-CBD1 antibodiesis of interest to note that the mean concentration of
the human mAb 2F5 against the “Katinger epitope” would result in a drastic reduction of antibody concen-
tration, and thus their efficacy.662ELDKWA667 in gp41 required for 90% inhibition of
HIV-1 has been reported to be around 20g/ml (D’Souza
et al., 1997). The capacity of anti-CBD1 antibodies to Reactivity of HIV-1-Positive Human Sera with CBD1
Sera from healthy individuals did not react with CBD1.inhibit HIV infection suggests that they exert their inhibi-
tory effect by binding to the CBD1-epitope in gp41. On the other hand, a small proportion of sera from HIV-
1-infected individuals with high antibody titers againstConsistent with this, the anti-CBD1 immune sera react
in ELISA with a recombinant preparation of gp41, but an immunodominant epitope in gp41 reacted weakly
with CBD1, thus indicating the rare presence of naturalnot with gp120 (Table 3). Successive immunization of
rabbits with the CBD1 peptide lead to a gradual increase antibodies against the CBD1-epitope (Table 3). This lat-
ter also suggests that the synthetic CBD1 peptide couldof the reactivity against gp41 and the CBD1 peptide,
reaching a maximum titer after four immunizations (Sup- be immunogenic in humans and thus provide a valuable
B cell epitope vaccine candidate against HIV. It shouldplemental Table S2). Interestingly, bleedings after four
and five immunizations (serum S4 and S5) were the ones also be noted that the conserved asparagine at position
625 in the CBD1-epitope represents a potential N linkedthat exerted a marked inhibition of HIV infection (Fig-
ure 3H). glycosylation site (N-X-T). Consequently, the synthetic
CBD1 peptide might have an advantage over the nativeThe HIV inhibitory activity of anti-CBD1 antibodies
was compared with that of a recombinant preparation caveolin-1 binding domain, which could hinder the de-
velopment of an immune response because of theof mAb 2F5 in an assay in which three primary isolates
of HIV-1 were used, HIV-1 IN12, SE365, and BZ167. In N-linked glycosylation (Rudd et al., 2001).
accord with our previous results (Table 2), there was
more than 90% inhibition of these HIV-1 isolates at 50- Discussion
fold dilution of the rabbit KUR S5 serum (Figure 3I, black
histograms). On the other hand, mAb 2F5 at 10 g/ml To our knowledge, this is the first description of a con-
served caveolin-1 binding motif in gp41 and the capacityhad no apparent effect on HIV-1 SE365 but markedly
inhibited HIV-1 IN12 and BZ167 (Figure 3I, gray histo- of CBD1-based peptides to elicit the production of anti-
bodies that inhibit infection of primary T lymphocytesgrams). Due to the fact that the 2F5 epitope is well
conserved, this latter might be the consequence of lower by the different primary HIV-1 isolates belonging to
clades A to G (Table 2). Anti-CBD1 antibodies act onaccessibility of the 2F5 epitope in the HIV-1 SE365 iso-
late compared to the other two isolates. More impor- two distinct steps on the HIV infectious cycle. (1) They
prevent infection of cells by HIV particles. (2) They causetantly, the inhibitory effect of both mAb 2F5 and anti-
CBD1 antibodies required the continual presence of aggregation of gp41 at the plasma membrane in HIV-
producing cells, leading to the production of defectivethese antibodies, since no inhibition occurred when in-
fected cells were washed extensively after the 90 min virus particles. Therefore, the CBD1-epitope is a suitable
target for the action of anti-HIV antibodies, since it isincubation period with HIV and the respective antibody
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suggest that the interaction of the CBD1 epitope in gp41Table 2. Broad Inhibitory Activity of Anti-CBD1 Antibodies against
with the caveolin-1-scaffolding domain in caveolin-1HIV-1 Infection
might be necessary for the proper trafficking of the HIV
HIV-1/HIV-2 Isolates ID95 ID50 nucleocapsid toward the actin cytoskeleton, which is
I the major site for viral reverse transcription in infected
cells (Bukrinskaya et al., 1998). Interestingly, caveolarHIV-1 LAI (B) 25 40
endocytosis is ligand triggered and involves extensiveHIV-1 Ba-L 25 50
HIV-1 ELI (D) 25 50 rearrangement of the actin cytoskeleton to deliver the
HIV-1 N199 25 50 ligand to the endoplasmic reticulum (Pelkmans et al.,
HIV-1 SR 50  100 2002). The principal site where caveolin-1 could be func-
*HIV-1 92UGO37 (A) 25 40 tional in the membrane traffic is at the caveolae, which
HIV-2 ROD 20 50
are implicated in transcytosis and the uptake of mem-HIV-2 CBL-20 20 40
brane components and extracellular ligands (Liu et al.,
II 2002; Smart et al., 1999; van Deurs et al., 2003). The
HIV-1 Ba-L 25 50 capacity of the six-helix bundle in gp41 to interact with
*HIV-1 BK132 (B) 25 40 lipid membranes (Shu et al., 2000), the observation that
*HIV-1 BZ167 (B) 50 150 the CBD1 peptide from gp41 specifically binds caveo-
*HIV-1 SE364 (C) 40 150 lin-1 (Figure 1), and the location of the caveolin-1-scaf-
*HIV-1 CM238 (E, A/E) 25 50
folding domain in caveolin-1 just adjacent to its trans-*HIV-1 BZ162 (F) 40 100
membrane domain all suggest that gp41 might interact*HIV-1 HH8793 (G) 25 100
with the caveolin-1-scaffolding domain once it is withinHIV-2 ROD No Effect No Effect
the plasma membrane. The caveolin-1-scaffolding do-III
main in caveolin-1 is arranged in an -helix structure,
*HIV-1 UG273 (A) 100 200 allowing assembly of caveolin-1 filaments in caveolae
*HIV-1 DJ258 (A) 50 75 through lateral interactions between the  helices of
*HIV-1 BZ167 (B) 40 100
several caveolin-1 units (Fernandez et al., 2002). Conse-*HIV-1 CM237 (B) 200  200
quently, the interaction of gp41 with caveolin-1 might*HIV-1 US3 (B) 150  200
be enforced by potential interactions between  helices*HIV-1 UG268 (C) 50 100
*HIV-1 SE365 (D) 100 150 of gp41 and caveolin-1. Whether the six-helix bundle
*HIV-1 IN12 (E, A/E) 150 200 splits apart before the interaction of gp41 with caveo-
HIV-2 ROD No Effect 20 lin-1 remains to be investigated. Whatever is the case,
HIV-2 EHO No Effect No Effect the recovery of caveolin-1 after immunoprecipitation of
The inhibitory action of the immune rabbit serum (bleeds S5) ALD gp41 from HIV-infected cells points out that under physi-
(section I), SAN (section II), and KUR (section III) raised against ological conditions gp41 binds caveolin-1.
CBD1 was tested in CD4 primary T lymphocyte cultures infected Caveolin-1 might also be implicated in the HIV bud-
with the T -lymphocyte tropic (X4) HIV-1 LAI, macrophage-tropic
ding process during the assembly of viral components(R5) HIV-1 Ba-L, X4 HIV-1 ELI isolate from Zaire, an isolate resistant
at lipid raft domains in the plasma membrane (Campbellto the nonnucleoside RT inhibitor nevirapine (HIV-1 N199), an isolate
et al., 2001; Ono and Freed, 2001). Electron microscopyresistant to the HIV protease inhibitor saquinavir (HIV-1 SR), labora-
tory adapted HIV-2 isolates (HIV-2 ROD, CBL-20, HIV-2 EHO), and studies have shown that the distribution of gp120-gp41
primary HIV-1 isolates (marked by an asterisk). Titers are the dilution complex in Env-expressing cells is restricted to elec-
of the immune serum at which HIV production was inhibited by 95 tron-dense crescent structures at the plasma membrane
and 50% compared to the control samples that were obtained by (Katsumoto et al., 1990; Laurent-Crawford et al., 1993).
using the respective preimmune rabbit S0 serum. No effect corre-
The binding of gp41 to caveolin-1 might trigger caveo-sponds to values 	10%. The HIV-1 clades are given in parenthesis.
lin-1 oligomerization (Harder et al., 1998) causing clus-
tering of the envelope glycoprotein-complex in the
plasma membrane. In contrast to HIV-producing cells
accessible both on HIV particles and on the envelope where caveolin-1 is associated with gp41, we did not
glycoprotein complex expressed on the surface of HIV- detect caveolin-1 associated with purified HIV particles,
producing cells. The existence of the gp41-caveolin-1 thus indicating that caveolin-1 is not incorporated into
complex in HIV-1 infected cells suggests that the anti- the budding virus (data not shown). Recently, the coex-
CBD1 antibodies might be functional, at least in part, pression of caveolin-1 with HIV-1 was reported to block
by inhibiting the potential interaction of gp41 with caveo- virus production mostly by inhibiting viral protein syn-
lin-1 during the viral membrane and cellular membrane thesis through its transmembrane domain (Llano et al.,
fusion processes. It might also be possible that anti- 2002). The mechanism of this inhibitory effect should
CBD1 antibodies affect the six-helix bundle formation be independent of the known function of caveolin-1 in
by modifying the conformation of gp41 and thus inhibit the organization of lipid rafts.
an early step of HIV entry independent of potential inter- The current B cell epitope vaccine candidates have
action of gp41 with caveolin-1. In vivo, anti-CBD1 anti- failed to generate broadly neutralizing antibodies against
bodies might also trigger elimination of HIV-infected HIV-1 (McMichael and Hanke, 2003). Antibodies against
cells by Fc-mediated effector systems, such as anti- gp120 are viral isolate specific due to the sequence vari-
body-dependent cellular and complement-mediated ability of gp120 and thus have limited usefulness (Moore
cytotoxicity (Parren and Burton, 2001). et al., 2001). The gp41-ectodomain by virtue of the con-
Although the function of caveolin-1 in the HIV entry served domains provides a good alternative vaccine
candidate; however, synthetic peptides correspondingprocess remains to be investigated, it is plausible to
Immunity
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Figure 3. Inhibition of HIV Infection by Anti-
CBD1 Antibodies
(A–C) Kinetics of HIV production in primary
CD4 T lymphocytes infected with HIV-1
Ba-L, SR, and HH8793 were investigated in
the presence of rabbit ALD preimmune (S0)
and immune (S5) serum at different dilutions
as indicated. The ordinate gives the concen-
tration of p24 (ng/ml) in culture supernatants.
(D and E) HIV particles produced in the pres-
ence of anti-CBD1 antibodies are less infec-
tious. The infectivity of HIV-1 Ba-L and HH8793
(at a dose of 75 ng/ml of p24) produced in
the presence of 100-fold dilution of the S5
bleeding (in [A] and [C], respectively), were
tested in HeLa P4C5 cells (Supplemental
Data). The background levels were obtained
by the addition of AZT. The numbers in brack-
ets give the net percentage reduction of in-
fectivity of HIV produced in cultures in the
presence of S5 compared with S0 bleeding.
(F) The anti-HIV activity is due to the action
of anti-CBD1 antibodies: rabbit DAV immune
S5 serum was purified by affinity chromatog-
raphy by using biotinyl-CBD1 bound to avi-
din-sepharose. The starting serum (S.S.), the
flow through (F.T.), and the purified material
(P.M.; elution with 100 mM glycine pH 2.5)
were titrated by ELISA (left ordinate; OD at
450 nm) and assayed for inhibition of HIV-1
LAI in MT4 cells (right ordinate). These sam-
ples were analyzed taking into consideration
the fold-dilution and the fold-concentration
of F.T. and P.M. samples, respectively.
(G) More than 90% inhibition of HIV-infection
occurs at 8 g/ml of anti-CBD1 IgG. Immune
sera S5 from rabbit KURT and LEO were puri-
fied as in section F and tested on HIV-1 LAI
infection in MT4 cells at 1, 2, 4, and 8 g/ml.
(H) Anti-HIV activity of successive bleeds
from rabbit KUR immunized with the CBD1
peptide. Primary CD4 T lymphocytes were
infected (as in Figure 2A) with the primary isolate HIV-1 BZ167 in the presence of 50-fold dilution of serum KUR (as shown in Table 1) before
(serum S0) and after different immunizations (S2–S5). On the right is the titer (OD 540 nm) of each serum against the CBD1 peptide and gp41
at 6400 and 400-fol dilution, respectively (ELISA was performed as in Table 3).
(I) The continual presence of anti-CBD1 immune serum is required for the inhibition of HIV infection. Three primary isolates of HIV-1 (IN12,
SE365, and BZ167) were preincubated (20C, 20 min) either with rabbit serum KUR S5 (at 50-fold dilution) or human mAb 2F5 (10 g/ml)
before incubation with primary CD4 T lymphocytes (37C, 90 min). Infected cells were then centrifuged and divided into two aliquots: one
aliquot was suspended in culture medium containing KUR and mAb 2F5 (as above), while the other aliquot was washed extensively (twice
with ten times the culture volume) with culture medium (i.e., RPMI containing 10% fetal-calf serum) before suspending in fresh culture medium.
Virus production was monitored by measuring the p24 concentration at 6 days postinfection. The ordinate gives the percentage of HIV
production in each sample by using as controls preimmune KUR serum S0 or HIV negative human IgG (Sigma).
to immunogenic epitopes in gp41 have failed to elicit infected individuals, CBD1-based vaccines could have
applications as a therapeutic vaccine in AIDS patients.the production of antibodies that inhibit HIV infection
(Golding et al., 2002; Moore et al., 2001). Similarly, anti-
Experimental Proceduresbodies raised against synthetic peptides containing the
epitope of the neutralizing human mAb 2F5 (Muster et
Peptidesal., 1994) do not inhibit HIV infection. The capacity of All peptides were synthesized in Fmoc chemistry by the stepwise
anti-CBD1 antibodies to block infection of primary lym- solid-phase methodology with a multichannel peptide synthesizer
phocytes by different HIV-1 isolates and the conserva- as previously described (Neimark and Briand, 1993). Peptides were
purified by reversed-phase HPLC and were identified by matrix-tion of the caveolin-1 binding motif among all viral iso-
assisted laser desorption and ionization time-of-flight (MALDI-TOF)lates indicate that CBD1-based peptides provide a
spectra on a Protein TOFTM mass spectrometer (Bruker, Wissem-universal B cell epitope that should be considered as a
bourg, France).
vaccine candidate for use in association with CTL-based
vaccines that are currently in clinical trials. Finally, since Reagents
natural antibodies against the CBD1-epitope are at low Various laboratory-adapted and primary isolates of HIV-1, the re-
combinant human mAb 2F5 produced in CHO cells, and the recom-titer and present in only a small proportion of HIV-
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Table 3. Reactivity of HIV-1 Positive Sera with the Caveolin-1 Binding Domain
ELISA/Peptides ELISA/CBD1 ELISA3/gp41
Serum1 Origin2 600–612 Peptides 618–633 aa 586–682
Rabbit SAR  0.18 0.12 0.15
Rabbit KUR  0.16 1.05 0.45
Rabbit LEO  0.18 0.62 0.47
Rabbit NOU  0.15 0.42 0.28
HIV-1 ve, n 
 81 France 81/81 (2.25  0.58) 4/81 (0.33  0.05) N.T.
HIV-1 ve, n 
 24 Chile 24/24 (2.02  0.53) 1/24 (0.30) N.T.
HIV-1 ve, n 
 22 Brazil 22/22 (1.50  0.66) 1/22 (0.75) N.T.
1 Sera were tested by ELISA for the presence of IgG antibodies against the immunogenic epitope in gp41 (Phan Chan Du et al., 2002) containing
the disulfide loop (peptides 600–612) and CBD1 (peptides 618–633). The immune rabbit serum SAR used as a control serum was raised against
a synthetic peptide corresponding to the C-terminal end of human nucleolin (Nisole et al., 2002b), whereas the other rabbit sera (bleeds S5)
were against CBD1 in gp41 (Table 1). The rabbit sera were tested at 1600-, 6400- and 400-fold dilution against peptides 600–612, cysteinyl-
CBD1 (peptide 618–623), and recombinant gp41 (residues 586–682), respectively. An OD value above 0.20 is considered positive.
2 Human HIV-1-positive and-negative sera were tested at 1000-fold dilution. The mean of OD values measured at 450 nm  SD (in parenthesis)
is given for each group (n 
 the number of sera tested). Sera from different countries were made available from previous studies (Belliard et
al., 2003; Desgranges et al., 1998). The IgGs in the sera from Chile react with peptides corresponding to the V3 loop of HIV-1 clade B
(Desgranges et al., 1998). The cutoff points of each assay were determined with the sera from 30 non-HIV-infected individuals from each
country. Test sera were considered positive when the OD values were higher than the mean OD  2 SD of the negative sera.
3 All rabbit immune sera raised against the CBD1 peptides were negative, with a recombinant preparation of gp120 (OD values 	0.15).
binant HIV-1 gp120 Ba-L produced in insect cells were obtained an HIV-1 positive patient serum and protein A sepharose (Laurent-
Crawford and Hovanessian, 1993). Purified proteins were eluted byfrom the AIDS Research and Reference Program/NIAID, NIH (AIDS/
NIH). The HIV-1 HxB2 gp41 recombinant fragment 586–682 pro- heating in the electrophoresis sample buffer and analyzed by SDS-
PAGE. The quantification of the intensity of the gp120 and p24duced in Pichia pastoris was from Advanced Biotechnologies.
bands was performed by using the NIH image software (Nisole et
al., 2002a).Immunization of Rabbits, Human Sera, and ELISA
Rabbits (Fauves de Bourgogne or New Zealand) were injected intra-
muscularly or intradermally with the different immunogens five dif- Confocal Microscopy
The crosslinking of cell bound HIV-1 and biotinyl-CBD1 (5 M) wasferent times with about 2 week interval between each injection. The
immunogens were either in complete Freund’s adjuvant/incomplete carried out with anti-HIV-1 human serum (AIDS/NIH) and a murine
mAb against biotin (Enzo Diagnostics), respectively. After partialFreund’s adjuvant (CFA/IFA; CFA for the first injection and IFA for
the other four injections), CFA or poly(A).poly(U) (Sigma) at 2 mg fixation (Nisole et al., 2002a), cells were incubated with rabbit anti-
caveolin-1 antibodies that react with both isoforms of caveolin-1per injection (Hovanessian et al., 1988). Peptides bound to streptavi-
din were used at 50 g, while the other peptides were used at 150 (BD Transduction Laboratories). The secondary antibodies were
Texas Red (TR) dye-conjugated goat anti-human (Vector Labora-g peptide/injection. The different sera were titrated by enzyme-
linked immunosorbent assay (ELISA) by using Maxisorp plates tories) or horse anti-mouse IgG (Valbiotech, Paris), and FITC-conju-
gated goat anti-rabbit IgG (Vector Laboratories) (Nisole et al.,coated with 2 M of each peptide (Phan Chan Du et al., 2002). HIV-
positive human sera were tested after heat inactivation (56C, 45 2002a, 2002b).
min). Control sera were from normal blood donors.
Immunoblotting and Coimmunoprecipitation Experiments
Cell extracts were prepared in lysis buffer I (50 mM Tris-HCl [pHCell Lines and Assay of HIV Infection
MT4 T lymphocytic cells and primary CD4 T lymphocytes were 7.6], 400 mM NaCl, 1 mM EDTA, 1% Triton X-100 and the protease
inhibitor cocktail from Roche) or buffer II (50 mM Tris-HCl, pH 7.6,propagated in RPMI-1640 containing 10% heat inactivated fetal-
calf serum and 50 IU/ml penicillin-streptomycin (Nisole et al., 2000). 25 mM KCl, 5 mM MgCl2, 1 mM EDTA, 0.5% NP-40 and the protease
inhibitors). Cells were suspended (4C, 30 min) in the lysis buffer,CD4 lymphocytes were prepared from PBMC after depletion of
CD8 cells with Dynabeads M-450 CD8. After 3 days stimulation centrifuged at 12,000  g for 10 min, and the nonionic detergent
soluble supernatants were collected. For immunoblotting, aliquotswith PHA, cells were suspended in fresh culture medium containing
IL-2 (Nisole et al., 2000) and infected after 24 hr. The maximum peak of the supernatants were diluted once in 2-fold concentrated poly-
acrylamide gel electrophoresis (PAGE) sample buffer (125 mM Tris-of virus production in such primary CD4 cells occurred at 5–7 days
postinfection instead of 8–12 days postinfection, as in the case of HCl [pH 6.8], 1% SDS, 0.1% bromophenol blue, 150 mM -mercap-
toethanol, and 20% (v/v) glycerol) and heated at 95C for 5 min. ThePBMC. HIV-1 isolates were propagated on primary CD4 cells. Un-
less specified in figure legends, inhibitory activity against HIV infec- pellet corresponding to the nonionic detergent insoluble fraction
was suspended directly in the 2-fold concentrated PAGE sampletion was assayed by preincubation (20C, 20 min) of a given HIV
isolate with various dilutions of the immune serum before incubation buffer. Immunoblotting was carried out as described before (Nisole
et al., 2002a) with murine anti-p17 mAb (Advanced Biotechnologies),(37C, 90 min) with permissive cells. Infected cells were suspended
in culture medium supplemented with the immune serum and cul- human anti-gp41 mAb D8 (Legastelois and Desgranges, 2000) and
rabbit anti-caveolin-1 (Transduction Laboratories), and anti-p24tured for 5–7 days (depending on the peak of virus production).
Cells were passaged on day 3 and virus production was monitored (AIDS/NIH) antibodies. The primary human, murine, and rabbit anti-
bodies were revealed by horseradish peroxidase-conjugated rabbitin culture supernatants by p24 ELISA (values obtained in different
experiments were at ng/ml). The mean  SD of triplicate samples is anti-human and anti-mouse IgG, and goat anti-rabbit IgG, respec-
tively (Amersham Pharmacia Biotechnologies).shown. The MOI of various HIV isolates used in different experiments
was 1 (Nisole et al., 2000). For the coimmunoprecipitation experiments, cell extracts in lysis
buffer I were diluted 5-fold in low salt buffer (10 mM Tris-HCl [pHFor metabolic labeling, cells were cultured in RPMI medium defi-
cient in methionine/cysteine but supplemented with 200 Ci of 7.6], 10 mM KCl) before addition of murine mAbs anti-p17 and anti-
gp41 (NEN Life Science Products, Inc.). The immune complexes[35S]methionine/cysteine (ProMix; Amersham Biosciences) for 24 hr.
Culture supernatants were filtered and centrifuged at 100,000  g recovered with protein A/G sepharose were washed extensively with
buffer I containing 50 mM NaCl and eluted in the electrophoresisto pellet HIV. Cell and viral extracts were immunoprecipitated with
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sample buffer containing SDS. For disruption of lipid rafts, cell ex- domain structure of the plasma membrane revealed by patching of
membrane components. J. Cell Biol. 141, 929–942.tracts were pretreated (4C, 20 min) with 60 mM n-octyl glycoside
(OTG) before immunoprecipitation with the murine anti-gp41 mAb. Harris, J., Werling, D., Hope, J.C., Taylor, G., and Howard, C.J.
(2002). Caveolae and caveolin in immune cells: distribution and func-
tion. Trends Immunol. 23, 158–164.Acknowledgments
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